Tumor‑targeting templated silica nanoparticles as a dual‑drug delivery system for anti‑angiogenic ovarian cancer therapy
- Authors:
- Published online on: July 11, 2017 https://doi.org/10.3892/etm.2017.4777
- Pages: 2162-2170
-
Copyright: © Zheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
The present study indicated the successful construction of a silica nanoparticle (SLN)‑based drug delivery system (DDS) for the tumor‑targeted co‑delivery of two anti‑angiogenic drugs, candesartan (CD) and trastuzumab (Tra), for ovarian cancer therapy via different anti‑angiogenic mechanisms using hyaluronic acid (HA)/Tra/CD/SLNs. In vitro and in vivo anti‑angiogenic assays indicated that CD and Tra exert beneficial functions on suppressing cancer angiogenesis, and exhibited significantly enhanced effects compared with the angiotensin stimulated group (P<0.01). CD and Tra co‑delivery also significantly increased the anti‑angiogenic effect compared with applying either drug alone (P<0.01). Furthermore, HA on the surface of the DDS was demonstrated to reduce the cytotoxicity of the DDS and also endowed the particles with an advanced tumor‑homing property in vitro and in vivo. The present results revealed that HA/Tra/CD/SLNs may be a preferable formulation for anti‑angiogenic ovarian cancer therapy.
